Abbott Laboratories (ABT) is positioned for multi-pronged growth driven by its diagnostics, nutrition, and medtech segments, with management targeting a 7% organic growth rate. The recent acquisition of EXAS adds some balance sheet and bottom-line risks but introduces a new Cancer Diagnostic segment that is growing at double-digit rates. Despite near-term risks, especially in the seasonally softer Q3, ABT's current cheap valuations, attractive dividend yields, and strong long-term price target of $139 support a bullish investment case. The stock remains a recommended buy for investors willing to accept some short-term volatility.
Abbott Laboratories has seen a strong rally since May, supported by growth in its core Medical Devices segment and the recent acquisition of Exact Sciences. The company holds an A+ credit rating with a stable outlook, and its shares currently trade a...
Abbott Laboratories reported strong Q2 earnings that exceeded expectations, driving its stock up 14%. The company also raised its full-year 2026 guidance, signaling confidence in future growth. Key business areas like diagnostics and electrophysiolog...
UK GDP grew 0.8% over three months, surpassing forecasts and showing resilience despite geopolitical tensions and energy price pressures. The FTSE 100 opened lower as investors digested takeover deals including Rotork's £4.1bn acquisition by ABB and ...
Abbott posted a 13% increase in reported sales and 4.8% comparable sales growth for Q2 2026, with GAAP diluted EPS at $0.53 and adjusted EPS at $1.31. The company reaffirmed its full-year 2026 sales growth guidance of 6.5% to 7.5% and raised its adju...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
